Currently, OTEZLA (apremilast) is the only approved medication specifically indicated for treating mild to moderate plaque psoriasis. OTEZLA is an oral small-molecule drug that selectively ...

Otezla was acquired by Amgen for $13.4 billion ... to defend its product by expanding the label of the drug to include mild psoriasis. Last December, it secured FDA approval for the treatment ...

"Tapinarof cream could become a highly beneficial treatment option for adult patients living with mild, moderate and severe plaque psoriasis ... oral PDE4 inhibitor Otezla (apremilast ...

Generalized Pustular Psoriasis, Mild to Moderate Plaque Psoriasis, and Moderate to Severe Psoriasis. These reports include a comprehensive understanding of current treatment practices, emerging ...

Once-daily roflumilast foam significantly improves scalp and body psoriasis in 8 weeks and was well-tolerated in adolescents ...

Topical therapy remains the standard of care, especially for mild to moderate cases. These cases are often managed with topical glucocorticoids, vitamin D analogs, and phototherapy. In contrast, ...

India Bolton, 25, doesn't always have visible psoriasis flares. But there are times when her psoriasis becomes so severe that she barely feels like herself. Below, she shares how she's learned to ...

While there are plenty of over-the-counter psoriasis treatments, you’ll probably need a prescription medication unless you have a very mild case. Psoriasis can cause red, dry, itchy skin patches ...

Artelo Biosciences advances ART26.12 for psoriasis and CIPN, while ART27.13 shows early promise in cancer-related anorexia ...

NASHVILLE, Tenn. (WSMV) - Off and on showers are likely both Wednesday and Thursday. This afternoon will remain sunny and gorgeous! Count on highs in the low to mid 70s with little to no wind ...

A tremor of 3.4 magnitude hit north Gujarat in the wee hours of Saturday (May 3, 2025), the Institute of Seismological Research (ISR) stated. According to the district authorities, there was no ...

The dosing interval for ixekizumab may be extended in some patients with plaque psoriasis, and switching between biologics may also be considered.